Immatics N.V
NASDAQ:IMTX 10:51:15 AM EDT
| Market Cap (Intraday) | 655.88M |
| Current PE | 19.31 |
| Forward PE | 12.54 |
| 2yr Forward PE | N/A |
| 10-Day MA | $8.41 |
| 50-Day MA | $9.13 |
| 200-Day MA | $9.61 |
Immatics N.V Stock, NASDAQ:IMTX
Paul-Ehrlich-Strasse 15, Tuebingen, Baden Wuerttemberg 72076
Germany
Phone: +49.7071.5397.0
Number of Employees: 255
Description
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.